Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 5617 to 5618 of 5618 entries
Sorted by: Best Match Show Resources per page
Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Contrast media & molecular imaging

Dong Y, Zhou X, Zhang Y, Liu Y, Zhou X, Ren G, Li Q.
PMID: 35024012
Contrast Media Mol Imaging. 2021 Dec 22;2021:3800211. doi: 10.1155/2021/3800211. eCollection 2021.

OBJECTIVE: To investigate the expression and clinical significance of serum heparin-binding protein (HBP), C-reactive protein (CRP), and white blood cell count (WBC) in an acute exacerbation of chronic obstructive pulmonary disease (COPD).METHODS: A prospective research model was used to...

Cite
Dong Y, Zhou X, Zhang Y, et al. Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Contrast Media Mol Imaging. 2021;2021:3800211doi: 10.1155/2021/3800211.
Dong, Y., Zhou, X., Zhang, Y., Liu, Y., Zhou, X., Ren, G., & Li, Q. (2021). Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Contrast media & molecular imaging, 20213800211. https://doi.org/10.1155/2021/3800211
Dong, Yuan, et al. "Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease." Contrast media & molecular imaging vol. 2021 (2021): 3800211. doi: https://doi.org/10.1155/2021/3800211
Dong Y, Zhou X, Zhang Y, Liu Y, Zhou X, Ren G, Li Q. Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Contrast Media Mol Imaging. 2021 Dec 22;2021:3800211. doi: 10.1155/2021/3800211. eCollection 2021. PMID: 35024012; PMCID: PMC8716236.
Copy Download .nbib Format: NLM
A novel immune-related gene signature predicting survival in sarcoma patients.

Molecular therapy oncolytics

Ren H, Bazhin AV, Pretzsch E, Jacob S, Yu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, Angele MK, Bösch F.
PMID: 35024438
Mol Ther Oncolytics. 2021 Dec 09;24:114-126. doi: 10.1016/j.omto.2021.12.007. eCollection 2022 Mar 17.

Sarcomas are a heterogeneous group of rare mesenchymal tumors. The migration of immune cells into these tumors and the prognostic impact of tumor-specific factors determining their interaction with these tumors remain poorly understood. The current risk stratification system is...

Cite
Ren H, Bazhin AV, Pretzsch E, et al. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncolytics. 2021;24:114-126doi: 10.1016/j.omto.2021.12.007.
Ren, H., Bazhin, A. V., Pretzsch, E., Jacob, S., Yu, H., Zhu, J., Albertsmeier, M., Lindner, L. H., Knösel, T., Werner, J., Angele, M. K., & Bösch, F. (2022). A novel immune-related gene signature predicting survival in sarcoma patients. Molecular therapy oncolytics, 24114-126. https://doi.org/10.1016/j.omto.2021.12.007
Ren, Haoyu, et al. "A novel immune-related gene signature predicting survival in sarcoma patients." Molecular therapy oncolytics vol. 24 (2022): 114-126. doi: https://doi.org/10.1016/j.omto.2021.12.007
Ren H, Bazhin AV, Pretzsch E, Jacob S, Yu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, Angele MK, Bösch F. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncolytics. 2021 Dec 09;24:114-126. doi: 10.1016/j.omto.2021.12.007. eCollection 2022 Mar 17. PMID: 35024438; PMCID: PMC8718575.
Copy Download .nbib Format: NLM
Showing 5617 to 5618 of 5618 entries